PWID and HCV-related parameters |
|
|
|
PWID HCV chronic prevalence in 2015 |
|
– |
45 – 65%, uniform distribution |
Contact tracing data33
|
Average infection rate |
|
per year |
Varied to fit sampled HCV prevalence in 2015, and increased by factor after 2010 to achieve 4–7 fold increase in incident infections |
Acute HCV surveillance data34,35
|
Average proportion of infections that spontaneously clear |
|
– |
0.22 – 0.29, uniform distribution |
32 |
PWID recruitment rate |
|
per year |
Varied to fit total population of 436–600 PWID in 2015, and increased by factor after 2008 to fit 2–3 fold increase in PWID population between 2008–2013 |
Contact tracing data33 and TEDs data36
|
Increase in PWID population size between 2008 and 2013 |
p |
|
2 – 3, uniform distribution |
TEDs data36
|
Average duration of injecting until cessation |
|
years |
5 – 20, uniform distribution |
Unpublished Scott county SSP data and other data23,37–39
|
Average drug-related mortality rate |
|
per year |
0.57% (0.41–0.73%), Poisson distribution |
USA sites from40
|
Average non drug-related mortality rate |
|
per year |
0.14%, Poisson distribution |
41 for 35–39 year olds in US |
Treatment parameters |
|
|
|
|
SVR rate |
|
– |
85 – 95%, uniform distribution |
43 |
Duration of treatment |
|
weeks |
12 |
Treatment number |
|
number per year |
Varied to reduce HCV prevalence or incidence by 90% by 2020/25/30. |
|
Harm reduction intervention parameters |
|
|
Relative risk of acquiring HCV while: |
|
|
|
On MAT |
|
– |
0.50 (0.40–0.63), log normal distribution |
Cochrane Systematic review13
|
On SSP |
|
– |
0.44 (0.24–0.80), log normal distribution |
On both MAT and SSP |
|
– |
0.29 (0.13–0.65), log normal distribution |
Duration on MAT/SSP |
1/
|
years |
0.99 (0.64–1.50), normal distribution |
42 |
Recruitment rate MAT |
|
per year |
Varied to give 25% or 50% coverage by mid-2017 |
|
Recruitment rate SSP |
|
per year |
Varied to give 50% coverage by mid-2016 |
|